Y-mAbs Reports EMA’s Acceptance of Pediatric Investigation Plan for Omburtamab

 Y-mAbs Reports EMA’s Acceptance of Pediatric Investigation Plan for Omburtamab

Y-mAbs Reports EMA’s Acceptance of Pediatric Investigation Plan for Omburtamab

Shots:

  • EMA has agreed to the Y-mAbs’ proposed Pediatric Investigation Plan (“PIP”) for Omburtamab which follows EMA’s Pediatric Committee’s positive opinion
  • The PIP approval allows Y-mAbs to file MAA of Omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma with its anticipated submission in H2’20
  • Omburtamab is mAb targeting B7-H3, being developed by Y-mAbs to treat CNS/leptomeningeal metastases from neuroblastoma, indication targeted by the PIP + number of additional cancer indications

Click here to­ read full press release/ article | Ref: Y-mAbs | Image:  Y-mAbs

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post